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Background: Vitamin C may enhance nitric oxide (NO) production through stepwise reduction of dietary
nitrate (NO3) to nitrite (NO2) to NO. The combined effect of vitamin C and NO3 supplementation is
relatively unexplored in untreated hypercholesterolemia.
Aims: We aimed to examine whether co-administration of vitamin C and nitrate for 4-weeks would
improve endothelial function (primary outcome), plasma NO metabolites, oxidative stress, and blood
lipids (secondary outcomes).
Methods: Subjects 50e70 years of age with low density lipoprotein (LDL) > 130 mg/dL and RHI 2 were
enrolled in this randomized double-blind crossover study. Subjects were assigned to two 4-week supplementation treatments starting with 70 ml of concentrated beetroot juice (CBJ) with 1000 mg of
vitamin C (NC) or CBJ with matched placebo (N), then switched to alternate treatment following 2-week
washout. The change in reactive hyperemia index (RHI), sum of plasma NO metabolites (NO2 þ NO3
(NOx)), oxidized LDL (oxLDL), and serum lipids were assessed at baseline and at 4-weeks of each
treatment period.
Results: Eighteen subjects (11M:7F) completed all study visits. No signiﬁcant treatment differences were
observed in RHI change (N: 0.21 ± 0.12; NC: 0.20 ± 0.17; p ¼ 0.99). Secondary analysis revealed that a
subgroup of NC subjects who started with a baseline RHI of <1.67 (threshold value for ED) had greater
improvements in RHI compared to subjects with RHI >1.67 (1.23 ± 0.15 to 1.96 ± 0.19; n ¼ 8 vs. 1.75 ± 0.11
to 1.43 ± 0.10; n ¼ 8; p ¼ 0.02). Compared to N, NC experienced a signiﬁcant increase in plasma NOx (N:
94.2 ± 15.5 mmol/L; NC: 128.7 ± 29.1 mmol/L; p ¼ 0.01). Although there was no signiﬁcant difference in
oxLDL change between treatments (N: 1.08 ± 9.8 U/L; NC: 6.07 ± 9.14 U/L; p ¼ 0.19), NC elicited
signiﬁcant reductions in LDL (N: 2.2 ± 2; NC: 10.7 ± 23; p ¼ 0.049), triglycerides (N: 14.6 ± 43;
NC: 43.7 ± 45; p ¼ 0.03), and no change in serum high density lipoprotein. Within treatment group
comparisons showed that only NC reduced oxLDL signiﬁcantly from baseline to 4 weeks (p ¼ 0.01).
Conclusions: No between intervention differences were observed in RHI. RHI only improved in NC
subjects with ED at intervention baseline. Four weeks of NC enriched the NO pool and promoted
reduction of blood lipids and oxidative stress in subjects with hypercholesterolemia. These preliminary
ﬁndings highlight a supplementation strategy that may reduce the progression of atherosclerotic disease
and deserves further attention in studies using ﬂow mediated dilation methods.
Clinical trial registration: www.clinicaltrials.gov (NCT04283630).
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
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Dietary inorganic nitrate supplementation leads to increased
nitric oxide (NO) generation and has received attention for its potential role in reversing endothelial dysfunction (ED) [1e3]. Low
serum and tissue NO status is a hallmark of ED that is associated

https://doi.org/10.1016/j.clnu.2020.10.012
0261-5614/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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reduction step of nitrite to NO [23]. The interaction between nitrate
and vitamin C has been recently described in the literature and has
indicated that vitamin C acts as an enhancer to catalyze the conversion of acidiﬁed nitrite to NO, thus, increasing the NO pool
[23e27].

Abbreviations
AS
CBJ
CVD
CVRFs
ED
eNOS
HDL
LDL
N
NC
NO
NO2
NO3
NOx
oxLDL
RH-PAT
RHI
TC
TG

atherosclerosis
concentrated beetroot juice
cardiovascular disease
cardiovascular risk factors
endothelial dysfunction
endothelium nitric oxide synthase
high density lipoprotein cholesterol
low density lipoprotein cholesterol
dietary nitrate supplementation alone
dietary nitrate and vitamin C supplementation
nitric oxide
nitrite
nitrate
sum of nitric oxide metabolites
oxidized low density lipoprotein
reactive hyperemia peripheral artery tonometry
reactive hyperemia index
total cholesterol
triglycerides

NOe
2 þ Hþ / HNO2
2 HNO2 þ vitamin C / 2  NO þ dehydroascorbic acid þ2 H2O
Although dietary nitrate and vitamin C have been independently linked to augmentation of NO and reducing oxidative stress,
there is a paucity of data that have examined the combined supplementation effect on cardiovascular health among patients with
CVRFs. Recently, Ashor et al. (2019) [22] demonstrated a signiﬁcant
synergistic effect following a single co-administered dose of
vitamin C with dietary nitrate in healthy individuals. Results
showed improvements in arterial stiffness as measured by pulse
wave amplitude, 3-nitrotyrosine concentrations, and blood pressure compared to vitamin C or nitrate given separately. However,
this combination did not improve endothelial function in all groups
as measured by post-occlusion reactive hyperemia. Studies of
longer duration designed to provide daily combined dosing of these
supplements interventions have yet to be conducted.
We aimed to examine whether co-administration of vitamin C
and nitrate for 4-weeks would improve markers of endothelial
function (primary outcome), plasma NO metabolites, oxidative
stress, and blood lipids (secondary outcomes). On the basis of their
complementary mode of action to augment NO and improve
endothelial function, we hypothesized that daily co-administration
of inorganic NO-3 and vitamin C for 4-weeks would elicit a greater
improvement in endothelial function as a result of changes in
reactive hyperemia index (RHI) score and other blood biomarkers
such as NO metabolites, oxLDL, and lipid proﬁle compared to nitrate alone.

with most cardiovascular risk factors (CVRFs) and cardiovascular
events [4e6]. NO is a vasodilator and anti-atherogenic molecule that
maintains vascular homeostasis and modulates in vitro lipid peroxidation reactions [7]. NO presents in circulation from two pathways but direct in vivo measurement of NO cannot be measured due
to its short half-life (milliseconds) [8e10]. NO is rapidly autooxidized to nitrate and nitrite in circulation when it is synthesized
from its primary endogenous precursor (arginine) by endothelium
nitric oxide synthase (eNOS) enzyme [11]. In the presence of CVRFs,
dietary nitrate provides an exogenous source and alternate pathway
of NO generation when eNOS is compromised [11]. Thus, in both
pathways, nitrite and nitrate act as stable end products that reﬂect
total systemic NO concentrations [10] and their plasma concentrations can be used as surrogate measures of vascular NO bioavailability [4]. Combined measurements of NO metabolic pathway
products (nitrate þ nitrite) are termed as NOx [12].
There is a growing interest in examining the utility of dietary
nitrate on the management and reversal of ED and attenuating
oxidative stress biomarkers [13,14]. Oxidative stress is a key
mediator contributing to the promotion of ED and atherosclerosis
(AS) in subjects with CVRFs, and may be counteracted with strategies designed to preserve endothelial NO [15e17]. Promising
ﬁndings from preclinical studies reported that inorganic nitrate
supplementation was able to reduce well-established markers of
oxidative stress, such as malondialdehyde and pro-inﬂammatory
cytokines [18,19]. To our knowledge, few clinical trials have investigated the effect of inorganic nitrate supplementation on different
markers of oxidative stress [1,20,21]. One of these studies reported
a trend in oxLDL reduction in untreated hypercholesterolemic
subjects following 6 mmol of dietary nitrate supplementation [1].
Borsa et al. [12] reported that systemic NO was negatively correlated with circulating oxLDL in hyperlipidemic elderly patients.
Further studies are needed to better understand the use of dietary
nitrate in relation to circulatory oxLDL in hypercholesterolemia and
to further elucidate the dietary nitrate beneﬁt on oxidative stress
associated ED [1].
Vitamin C plays a role in enhancing the exogenous NO pathway
through the stepwise reduction of dietary nitrate to nitrite and then
NO [22]. Under hypoxic and acidic condition in the blood and
gastric lumen, the presence of vitamin C may augment the second

2. Materials and methods
2.1. Subjects
Male and female non-smokers between the age of 50 and 70
with a body mass index (BMI) of 18.5e34.9 kg/m2 and high LDL
concentrations (>130 mg/dL) were enrolled. This age range was
chosen to target individuals more prone to hypercholesterolemia
and endothelial abnormalities [28]. The BMI range was selected to
examine whether our intervention would have different effects on
different BMI classes.
Subjects were excluded if receiving lipid lowering therapy,
multivitamin supplements exceeding recommended dietary
allowance (RDA), or on hormone replacement therapy, clonidine,
proton pump inhibitors (PPI), or antibiotic medications. Moreover,
subjects who consumed greater than 6 servings of alcohol per
week, performed resistance or aerobic training for more than 1hour four times per week, or participated in other clinical interventions within the previous 30 days were excluded from the
study. Subjects with a documented history of CVD, diabetes mellitus, chronic inﬂammatory disease, celiac disease, uncontrolled
hypertension, hepatic or renal disease, and active cancer were not
included in the study. Final enrollment decisions were contingent
upon having an RHI 2.
This study was approved by the university Institutional Review
Board, and the informed written consent was obtained from all
subjects prior to engaging in baseline measures. All institutional
and governmental regulations concerning the use of human volunteers were followed during this research. All study visits were
1852
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and nitrite, vitamin C, oxLDL, total cholesterol (TC), triglycerides
(TG), low-density lipoprotein (LDL), and high-density lipoprotein
(HDL) concentrations. Our washout length was chosen based on
previous work showing that a 2-week washout returned NO metabolites and vitamin C to baseline concentrations [35,36].
Prior to each visit, including screening visit stage 2, subjects
were asked to perform the following to prepare for vascular testing:
1) consume a low-nitrate diet for 48 h [35]; 2) refrain from taking
anti-hypertensive agents and long-acting vasoactive medications
including steroids, beta-blockers, antacids, anticoagulants, calcium
channel blockers, angiotensin converting enzyme inhibitors (ACEinhibitors), and aspirin for 24 h; 3) abstain from alcoholic beverages, coffee, high fat foods, chewing gum; 4) abstain from strenuous
exercise for 24 h [1]; and 5) fast for 12 h prior to study visit [32].
Throughout the intervention periods, subjects were instructed
to avoid high vitamin C foods and maintain their usual dietary
patterns throughout the duration of the washout period. At the
beginning of the study, subjects were provided with a list of high
vitamin C foods and vitamin C fortiﬁed foods to avoid during both
intervention periods. Dietary intake was assessed via 24-hr dietary
recall. Three 24-hour dietary recalls were collected and analyzed
using Nutrition Data System for Research (NDSR, Version 2019,
University of Minnesota, Minneapolis, MN, USA) at midpoint of
each interventional period, covering 1 weekend and 2 weekdays for
a total of 6 recalls.

conducted in the Center for Clinical and Translational Sciences
(CCTS), University of Kentucky, from February 2019 to September
2019. This study was registered with ClinicalTrials.gov
(NCT04283630).
2.2. Study design and randomization
This was a 10-week double-blind, placebo-controlled crossover
study. Randomization was conducted by the Investigational Drug
Service (IDS) at University of Kentucky. IDS prepared a randomization list treatment sequence. As subjects enrolled, they received
their intervention order and blinded supplement assignment.
Vitamin C and its placebo packaging were identiﬁed by the letter
“A” or “B” and therefore blinded to subjects and investigators. The
blinded supplements were then provided to the study coordinator
with the treatment allocation in a sealed envelope. The preparation
and labeling of the vitamin C and its placebo were performed in
such a way that both capsules were identical in shape, color, and
size to ensure adequate blinding of both subjects and investigators.
2.3. Study protocol
2.3.1. Screening visits
At screening visit 1 a phone screening or a face-to face interview
was performed to gauge subject's interest followed by assessing
BMI and screening for inclusion and exclusion criteria. At screening
visit 2 a non-invasive technique called Reactive Hyperemia Peripheral Artery Tonometry (RH-PAT) was employed to only include
subjects with RHI score 2. RH-PAT is intended for detection of ED
since the decline of endothelium-derived NO bioavailability is reﬂected by impaired RH-PAT vascular responses [29,30]. The main
advantages of this system are that it is operator independent, less
expensive, provides automated analysis, and easily performed [30].
In addition, validation studies reported that lower RHI is associated
with several cardiovascular risk factors [31e34].

2.4. Endothelial function measurement
Reactive hyperemia peripheral artery tonometry (RH-PAT) was
used to assess endothelial function in peripheral arteries. RH-PAT is
a non-invasive technique comprised of two ﬁnger plethysmographic probes connected to the EndoPAT-2000 device (Itamar
Medical, Caesarea, Israel) to measure changes in arterial pulsatile
volume induced by reactive hyperemia. EndoPAT tests occurred at
approximately 10 AM at each visit. Measures were performed in a
temperature-controlled room (70e75  F [21e24  C]) and the subject was asked to lie in a supine position for the procedure [32].
RH-PAT examination included three stages: pre occlusion, occlusion, and post occlusion. A manual blood pressure cuff was
placed on the upper arm of the non-dominant hand (occlusion
arm) to initiate PAT measurement. Then, two plethysmography
probes were placed on both index ﬁngers of each hand and inﬂated.
Subjects were asked to stay as still as possible during the entire

2.3.2. Study visits
Subjects completed 4 visits as described in Fig. 1. Each visit includes anthropometric measures, blood pressure, vascular testing,
and blood collection. Vascular testing was deﬁned as measures of
RHI ratio (primary outcome). Venous blood samples were collected
at baseline and endpoint visits of each intervention period
following an overnight fast. Plasma was used to measure nitrate

Fig. 1. Schematic representation of the study design. NO3: inorganic nitrate from concentrated beetroot juice dietary supplement.
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Fig. 2. Consort diagram of the progress through the phases of a crossover randomized trial of two treatment groups.

testing period. Following a 10 min rest period, the blood pressure
cuff was inﬂated manually to suprasystolic pressures by adding at
least 60 mmHG above systolic BP for ﬁve minutes. The cuff was then
deﬂated quickly and the EndoPAT device continued recording pulse
wave response for ﬁve minutes [29,37]. The RHI value was calculated automatically by dividing post-occlusion pulse wave amplitude (PWA) to the pre-occlusion value of PWA of the same arm,
normalized to the control arm, and then multiplied by baseline
correction factor [29,37].

measured using ELISA kit (Mercodia kit, Uppsala, Sweden) based on
the monoclonal antibody 4E6 [39]. Fasting plasma TG and TC concentrations were determined enzymatically using the Speciﬁc
Clinical Chemistry Analyzer. Heparine manganese chloride precipitation of plasma was used to measure high-density lipoprotein
(HDL) cholesterol. LDL concentration was calculated by the Friedewald formula [40].

2.5. Plasma biomarkers

The nitrate supplement was a commercially available beetroot
juice beverage (Sport Beet IT shot, Heartbeet Ltd). Sport Beet IT was
a concentrated beetroot juice (CBJ) (70 ml) that delivered an
average of 400e450 mg (~6.4 mmol) dose of inorganic nitrate per
the 70 ml serving [2]. The dietary nitrate dose was chosen due to
documented safety and efﬁcacy in previous studies that have
shown improvements in vascular health or a reduction in blood
pressure with no signs of toxicity [41e43]. Vitamin C (Nature Made
®), and the placebo (corn starch) were provided as supplement
capsules based on the randomization order. The selected dose of

2.6. Dietary supplementation

Fasting blood samples were drawn by trained staff at the University of Kentucky's CCTS immediately following vascular testing.
Plasma samples were stored at 80  C for analysis at a later time.
Plasma nitrate and nitrite were analyzed using Parameter™ Assay
Kit KGE001 (R&D Systems, Minneapolis MN, USA). The result was
read using the Griess Reaction @ 540e570 nM [38]. Plasma vitamin
C concentrations were analyzed using high performance liquid
chromatography (HPLC, ESA Inc.). Plasma oxidized LDL was
1854
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vitamin C (1000 mg) was based on observations from a previous
meta-analysis and systematic review reporting a minimum of
1000 mg of vitamin C per day elicited an improvement in endothelial function [44]. The study coordinator instructed subjects to
self-administer CBJ for 7 days a week at the same time by mouth
daily during the morning hours and then consume 2 capsules
(1000 mg of vitamin C or placebo) one hour later. Supplement
adherence was assessed by counting unused capsules and CBJ
bottles at each intervention endpoint.

Table 1
Baseline characteristics.
Variables

Male sex, n (%)
Age (years)
BMI (kg/m2)
Subjects on BP
medications n (%)
Plasma vitamin C (mg/dL)
Plasma NO3 (mmol/L)
Plasma NO2 (mmol/L)
Plasma NOx (mmol/L)
RHI
Plasma oxLDL (U/L)
Plasma TC (mg/dL)
Plasma LDL (mg/dL)
Plasma HDL (mg/dL)
Plasma TG (mg/dL)

2.7. Statistical analysis
Using the nQuery Advisor program, sample size calculations
were based on the work of Kwak et al. (2012) [45]. Based on these
data, nineteen subjects were needed for 80% power with a twosided p-value of 0.05 set for statistical signiﬁcance. Distribution
of continuous variables were examined by ShapiroeWilk test.
For within group comparisons, paired t-tests (for normally
distributed data) and Wilcoxon signed rank-test (for non-normally
distributed data) were employed using data at baseline and 4weeks for two interventional periods separately. Changes in measures over the 4-week period were assessed by calculating the
difference from baseline to 4 week in each treatment
(change ¼ endpoint-baseline). For between group comparisons, the
treatment effect (D) was evaluated by a two-sided one-sample ttest based on the mean of the differences between the two changes
for each pair (change during NC-change during N) [46].
Additionally, based on work by Wellek et al. [47], nonparametric
Wilcoxon tests were used to verify whether there were any carryover effects from one treatment period to another. An independent
sample t-test was used to assess the changes in RHI between highresponders and low-responders regardless of treatment group.
Linear mixed models were used to assess potential interaction effects of variables such as BMI and BP medication, sex, and age with
dependent variables. Pearson and Spearman correlations were
used to assess the relationship between dependent variables. Statistical analyses was performed using Statistical Package for Social
Sciences (SPSS) software (version 22, IBM, Armonk, NY). Data are
presented as means ± standard error of the mean (SEM).

Treatment N

Treatment NC

Total

(n ¼ 9)

(n ¼ 9)

(n ¼ 18)

3 (33%)
58 ± 1
29.6 ± 1
3 (33.3%)

4 (44%)
59 ± 2
27.1 ± 1.0
3 (33.3%)

7 (39%)
59 ± 1
28.3 ± 0.8
6 (33.3%)

0.73 ± 0.2
13.4 ± 1.8
0.44 ± 0.1
14.4 ± 1.8
1.55 ± 0.1
71.7 ± 2.9
235.4 ± 6.6
135.3 ± 6.1
55.1 ± 2.2
119.2 ± 16

0.88 ± 0.2
18.5 ± 2.8
0.46 ± 0.1
18.9 ± 2.8
1.66 ± 0.1
70.1 ± 4.2
249.1 ± 16.1
167.9 ± 13.7
54 ± 4.0
136 ± 18

0.81 ± 0.1
16.0 ± 1.7
0.45 ± 0.1
16.7 ± 1.7
1.60 ± 0.1
75.9 ± 2.9
242.3 ± 8.6
160.6 ± 7.5
54.56 ± 2.2
127.6 ± 11.9

BMI: body mass index; BP: blood pressure; NO3: nitrate; NO2: nitrite; NOx: nitric
oxide metabolic pathway products (nitrate (NO3) þ nitrite (NO2)); RHI: reactive
hyperemia index; TC: total cholesterol; LDL: low-density lipoprotein; HDL: highdensity lipoprotein; TG: Triglycerides. Quantitative variables were described as
the mean ± SEM. Data were analyzed using independent t-test (p > 0.05) and values
were not signiﬁcantly different between treatments at baseline.

Table 2
Response to 4-week supplementation with N and NC.
Value

Time point

N

NC

Plasma
NO3 (mmol/L)

Baseline
Endpoint
Change 1
Change 2 (D)
Baseline
Endpoint
Change 1
Change 2 (D)
Baseline
Endpoint
Change 1
Change 2 (D)

15.6 ± 1.3
94.2 ± 15.6
78.6 ± 15.4*
50.02y
0.42 ± 0.05
0.49 ± 0.05
0.07 ± 0.02*
0.03y
0.81 ± 0.10
0.66 ± 0.09
0.15 ± 0.12
0.58y

16.6 ± 1.9
145.3 ± 29.6
128.7 ± 29.1*

Baseline
Endpoint
Change 1
Change 2 (D)
Baseline
Endpoint
Change 1
Change 2 (D)
Baseline
Endpoint
Change 1
Change 2 (D)

15.6 ± 1.3
94.2 ± 15.6
78.6 ± 15.4*
50.02y
0.42 ± 0.05
0.49 ± 0.05
0.07 ± 0.02*
0.03y
0.81 ± 0.10
0.66 ± 0.09
0.15 ± 0.12
0.58y

Plasma
NO2 (mmol/L)

Plasma
Vitamin C (mg/dL)

Plasma
NO3 (mmol/L)

3. Results
Plasma
NO2 (mmol/L)

3.1. Subjects
Of the 23 subjects who enrolled, 18 completed both interventions and all study visits (Fig. 2). Further explanation of
subject attrition is found in Fig. 2. All baseline characteristics are
shown in Table 1. The interventions were generally well-tolerated
with no reports of severe adverse effects. Analyses of three dietary recalls at each treatment period indicated no signiﬁcant differences in dietary nutrient intake or dietary patterns (data not
shown).

Plasma
Vitamin C (mg/dL)

0.45 ± 0.06
0.49 ± 0.06
0.04 ± 0.03
0.77 ± 0.10
1.2 ± 0.13
±0.16*
16.6 ± 1.9
145.3 ± 29.6
128.7 ± 29.1*
0.45 ± 0.06
0.49 ± 0.06
0.04 ± 0.03
0.77 ± 0.10
1.2 ± 0.13
±0.16*

NO3: nitrate; NO2: nitrite. Change 1: the mean difference between baseline and
endpoint within treatment group. Values are reported as means ± SEM. *(p-value0.05, Paired t-test). Change 2: the mean difference between treatments. Data for
delta absolute value were analyzed using one sample t-test, yp < 0.05.

3.2. Adherence and subject response to supplementation

concentrations were signiﬁcantly increased compared to baseline
(p < 0.001) (Table 2). Likewise, the endpoint plasma nitrite concentrations were signiﬁcantly increased after N (p ¼ 0.006) but did
not increase after 4 weeks of NC (p ¼ 0.23) (Table 2). The change of
plasma NOx status between treatments was signiﬁcant (N:
94.24 ± 19.5 mmol/L; NC: 128.7 ± 29.1 mmol/L; p ¼ 0.01). Within
treatment group comparisons revealed that N and NC endpoint
NOx measures signiﬁcantly increased over time (p < 0.001) (Fig. 3).
Secondary analysis indicated that post-supplementation changes in
plasma NOx concentration correlated signiﬁcantly with changes in
plasma vitamin C following NC treatment (r ¼ 0.49, p ¼ 0.04) with
no correlation seen following N treatment (r ¼ 0.29, p ¼ 0.26).

Based on returned CBJ and capsule bottles and supplement diaries, more than 99% of CBJ and 98% of vitamin C distributed in both
interventional periods were reported to be ingested.
3.3. Nitrate, nitrite concentrations
Signiﬁcant differences were observed in the mean change of
plasma nitrate (D ¼ 50.02y, p < 0.01) and nitrite (D ¼ 0.03y,
p ¼ 0.03) between both treatment groups (Table 2). Within treatment group comparisons showed that endpoint plasma nitrate
1855
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Fig. 3. Functional and circulatory markers in response to N and NC interventions. RHI score (n ¼ 16) (A), NOx: nitric oxide metabolites (n ¼ 18) (B), oxLDL: plasma oxidized lowdensity lipoprotein (n ¼ 18) (C). (N): inorganic nitrate and vitamin C placebo or (NC): inorganic nitrate and active vitamin C (1000 mg). Data were analyzed using Paired t-test for
RHI and oxLDL, and Wilcoxon-test for plasma NOx, *p  0.05. D ¼ mean change between treatments. Data were analyzed using one sample t-test for delta absolute value, yp < 0.05.

course to the other (p ¼ 0.64). Within treatment group comparisons, revealed that RHI scores over time did not change signiﬁcantly in either treatment group (NC: p ¼ 0.24; N: p ¼ 0.09) (Fig. 3).
Secondary analysis revealed that some subjects responded
greater than others to NC treatment. Subjects were grouped into
“high-responders” and “low-responders” based on their RHI
response to NC treatment. High-responders (n ¼ 8) demonstrated
signiﬁcant increases in RHI in response to NC (1.23 ± 0.15 to
1.96 ± 0.19; p < 0.01), while the low-responders (n ¼ 8) had a
signiﬁcant decrease in RHI (1.75 ± 0.11 to 1.43 ± 0.10; p < 0.01).
Signiﬁcant differences were observed between RHI baseline scores
in high-responders and low-responders (p ¼ 0.02) (Fig. 4). No
notable interactions were detected among demographics and

3.4. Vitamin C concentrations
There was a signiﬁcant difference in plasma vitamin C change
between the treatments (D ¼ 0.58 y, p < 0.001). Within treatment
group comparisons showed that plasma vitamin C concentrations
increased signiﬁcantly over time following 4-week administration
of NC (Table 2).
3.5. Endothelial function
For our primary outcome, there were no treatment group differences in RHI change (N: 0.21 ± 0.12; NC: 0.20 ± 0.17; p > 0.05). No
evidence of carryover effect was observed from one treatment
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within groups comparisons. RHI improved only in a subgroup of
subjects with RHI values indicative of ED. Within treatment group
comparisons revealed that oxLDL was reduced over time only in the
NC intervention.
4.2. Reactive hyperemia index
There were no signiﬁcant differences in RHI between treatment
interventions. This is contrary to previous data that showed a
positive improvement in coronary endothelial function measured
by ﬂow mediated dilation (FMD) following 4e6 weeks administration of inorganic NO3 in subjects with CVRFs [1,2,30,48,49].
However, previous work by Ashor et al. has shown no effects of
nitrate combined with vitamin C on endothelial function using
laser Doppler measurements [22]. Comparisons between our
ﬁndings and the ﬁndings of others should be interpreted carefully
since these studies used different techniques to measure endothelial function. The absence of a signiﬁcant change in RHI in the
present study may have many other explanations. First, the hyperemic response in microcirculation beds is partly dependent on
NO [50] and other non-endothelium-dependent regulators [51,52]
while FMD response in conduit arteries is mainly NO mediated [53].
Thus, it has been suggested that RH-PAT may not be sensitive
enough to detect the inﬂuence of lifestyle modiﬁcations that target
NO pathway on microvascular beds [34,37,51]. An additional
explanation may be that the baseline RHI values of some subjects
were greater than 1.67. An RHI value below 1.67 was established by
EndoPAT as the threshold value to deﬁne subjects with coronary ED
[54]. Therefore, subjects with RHI baseline scores greater than this
cut point value may be less responsive to improvements in endothelial function. In our secondary subgroup analyses of RHI, it was
shown that the eight “high responder” subjects who showed an
individual increase in RHI following NC treatment (~60% improvements from baseline) had low baseline mean of RHI score
below the threshold value of 1.67. Fifty percent of the high responders achieved an increase in RHI to normal or above normal
values. These observations add novel ﬁndings and add to the work
from others that noticed substantial RHI improvements following
dietary interventions in subjects with ED [55,56].
While this was the ﬁrst study to examine the relationship between RHI and inorganic nitrate supplementation with and
without vitamin C supplementation, we were not able to verify if all
subjects took vitamin C exactly one hour following CBJ consumption. Proper timing of vitamin C ingestion 1 h after nitrate dosing is
thought to be important to permit adequate nitrate to enter the
enterosalivary circulation, thereby maximizing the reduction of
nitrite to NO in the gastric cavity as vitamin C consumed [57]. We
acknowledge that our ﬁndings may also suggest that subgroup
responders adhered with the timing of vitamin C ingestion more
than low responders.

Fig. 4. Change of RHI over time following NC treatment between high-responders and
low-responders. RHI score response was compared between high-responders (n ¼ 8)
and low-responders (n ¼ 8) before and after 4 weeks of NC. RHI: Reactive hyperemia
index. Subjects with greater change score in NC were deﬁned as high responders. Data
were analyzed using independent sample t-test to assess RHI baseline score between
high-responders and low-responders, *p  0.05.

baseline characteristics between the two treatment groups
(sequence 1: N-NC and sequence 2: NC-N) in terms of age, BMI,
gender, RHI, number of subjects on BP medication, vitamin C status,
and NO metabolite concentrations. Two subjects who started NC
treatment were excluded from RHI analysis due to poor RHI signals
at endpoint.
3.6. Oxidized LDL and blood lipids
Compared to N, there was no signiﬁcant differences observed in
the change of plasma oxLDL following NC (N: 1.08 ± 2.3 U/L;
NC: 6.07 ± 2.1 U/L; p ¼ 0.19). Within treatment group comparisons revealed that NC endpoint oxLDL was signiﬁcantly lower than
baseline (p ¼ 0.01) (Fig. 3). However, N endpoint oxLDL showed no
change over time (p ¼ 0.64).
Fasting lipid proﬁle analysis indicated that the mean change in
lipids was signiﬁcantly different following NC and N treatments for
LDL (N: 2.2 ± 3.5; NC: 10.67 ± 5.4; p ¼ 0.049) and TC (N: 0.17 ± 5.3;
NC: 16.06 ± 6.1; p ¼ 0.05). Serum HDL was unaltered between
treatment groups (N: 0.05 ± 0.8; NC: 0.33 ± 1.5; p ¼ 0.81). No
treatment carryover was evident in LDL (p ¼ 0.78), TC (p ¼ 0.73),
and HDL (p ¼ 0.93) analyses. However, there was a signiﬁcant
carryover effect in TG (p ¼ 0.03). As a result of this effect, we only
compared period one data for triglyceride changes between the
two treatments. We demonstrated a signiﬁcant difference in the
mean change of TG between treatments (N: 14.6 ± 14.2;
NC: 43.7 ± 14.9; p ¼ 0.01). Within treatment group comparisons
showed no change in TC (p ¼ 0.97), LDL (p ¼ 0.52), TG (p ¼ 0.33),
and HDL (p ¼ 0.95) from pre-to post following N treatment. In
contrast, there were signiﬁcant decreases in TC (p ¼ 0.02) and TG
(p ¼ 0.02) with a trend towards a reduction in LDL concentrations
from pre-to post following NC (p ¼ 0.06) (Fig. 5). HDL did not
change by time after NC treatment (p ¼ 0.83) (Fig. 5). Secondary,
exploratory analysis demonstrated that changes in plasma oxLDL
correlated signiﬁcantly with changes in plasma LDL following both
NC and N treatments (p < 0.01).

4.3. Circulatory biomarkers
As expected, the 4-week NC intervention yielded signiﬁcant
differences in NO3 and NO2 concentrations and reﬂect increased
capacity for NO production compared to N. The approximate 2-fold
increase in plasma NOx in NC compared to N support align with
previous studies suggesting that vitamin C acts as a potent reducing
agent to support nitrite reduction from the exogenous NO pathway
[24e28]. These ﬁndings are not aligned with recent crossover study
of Ashor et al. [22] who found no modifying effect of vitamin C on
plasma NO metabolites following acute dose of potassium nitrate
(5.1e8.7 mmol) ingestion combined with vitamin C (20 mg/kg) in
healthy individuals. This disparity could be due to the shorter
duration of their study and the differences in the population

4. Discussion
4.1. Summary of the main ﬁndings
NC did not improve RHI but signiﬁcantly increased NOx and
reduced blood lipids. Secondary analyses included subgroup and
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Fig. 5. Serum lipid proﬁle response to N and NC. TC: Total cholesterol (n ¼ 18) (4A), LDL: low-density lipoprotein (n ¼ 18) (4B), HDL: high-density lipoprotein (n ¼ 18) (4C), and TG:
triglycerides (n ¼ 9) (4D). (N): inorganic nitrate and vitamin C placebo or (NC): inorganic nitrate and active vitamin C (1000 mg). Data were analyzed using Paired t-test for all lipid
proﬁle parameters, *p  0.05. D ¼ mean change between treatments. Data were analyzed using one sample t-test for the absolute delta value, yp < 0.05.

effect of a single combined dose of nitrate and vitamin C on the
oxidative stress marker 3-nitrotyrosine [22]. As LDL peroxidation
and reduced NO synthesis are the two characteristic features of ED,
and share signiﬁcant antagonistic roles in overall vascular health, it
may be that any observed beneﬁt of NC on oxLDL may be driven by
NOx changes interacting with oxidants on the vascular wall [16].
This speculation requires further study and greater statistical power as the capacity of both bioactive substances as donors of NO
may have a direct effect on attenuating the lipid peroxidation reaction [12].
Moreover, we observed the NC intervention resulted in substantial reductions in TC (16.1 mg/dL or 6.6%), LDL (10.7 mg/dL
or 6.6%), and TG (43 mg/dL or 32%). These ﬁndings are of

studied. In addition, our 8.8 fold increase in plasma nitrate
following NC was greater than Velmurugan and colleagues [1] who
examined a similar nitrate dosage (~6 mmol) alone and reported a
7.5 fold nitrate increase in untreated hypercholesterolemia
patients.
In the present study, we did not observe between intervention
differences in oxLDL. Within group analysis of the N intervention
offer no evidence of oxLDL reduction and are consistent with previous work by Velmurugan et al. (2015) [1] who found no nitrate
induced changes in oxLDL in untreated hypercholesterolemic
adults. In contrast, we observed a signiﬁcant within group reduction in oxLDL (6.07 U/L) as a result of the NC intervention. These
ﬁndings are in accordance with recent work reporting a synergistic
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particular interest because of both the magnitude of change
observed and how they compare with a recent meta-analysis of
vitamin C treatment in hypercholesterolemic adults [58]. In this
meta-analysis, thirteen trials found that TC, LDL, and TG decreased
by 10.76 mg/dL (4.5%), 7.9 mg/dL (5%), and 20.1 mg/dL (8.8%),
respectively. In the present study, nitrate appeared to modify and
improve the lipid lowering effect of vitamin C. Our NC ﬁndings can
also be compared to a previous study [59] that combined a 30 day
inorganic nitrate administration along with the antioxidant hawthorn berry to reduce TG concentrations. The TG lowering effect
(32%) seen in our work was similar to the percentage of TG
reduction (27%) shown by Zand et al. [59]. Collectively, the improvements in blood lipids from our work and others suggest that
NO3 supplementation with the addition of vitamin C (or other
nutraceutical antioxidants), may be a valuable dietary approach to
combat dyslipidemia which could positively impact cardiovascular
health [60,61]. The exact mechanism of action to explain the serum
lipids ﬁndings remains to be determined, but may be partially
explained by complementary antioxidant effects of both supplements that work in concert to decrease oxidative stress [58,62e64].
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4.4. Strengths and limitations
This work has many strengths including study design with strict
inclusion and exclusion criteria and high supplement adherence.
Furthermore, the signiﬁcant increase of plasma NO metabolites
from baseline with or without vitamin C conﬁrmed excellent
adherence with CBJ and agree with previous ﬁndings that total
systemic NO bioavailability is strongly inﬂuenced by changes in
dietary nitrate in subjects with CVRFs [1,65]. There are also limitations to consider when interpreting results. The major limitation
was the small sample size that may have limited our ability to
observe signiﬁcant RHI differences between treatments or potential interactions between the dependent and independent variables. Although we observed differences between N and NC in most
dependent variables, comparison interpretations should be made
cautiously. A number of exploratory analyses of secondary outcome
variables were conducted for which the study was not powered.
Another limitation is that not all the subjects enrolled the study had
RHI <1.67. In addition, this study was not designed to examine the
effect of vitamin C alone, therefore, it is unknown if systemic NO
accumulation from NC has a direct effect on lipids and oxidative
biomarkers or if the direct beneﬁcial effect is explained by vitamin
C supplementation.
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